专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08709731B2 DKK1 oncogene as therapeutic target for cancer and a diagnosing marker 有权
标题翻译： DKK1癌基因作为癌症治疗靶点和诊断标志物
公开(公告)号：US08709731B2
公开(公告)日：2014-04-29
申请号：US12674660
申请日：2008-08-21
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： G01N33/53
CPC分类号： C07K16/32 , A61K2039/505 , C07K16/3046 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/574 , G01N2333/4703 , G01N2500/04 , G01N2800/50
摘要： Described herein are antibodies and antibody fragments capable of treating or preventing cancers associated with the over-expression and/or up-regulation of DKK1. Also disclosed are methods of treating or preventing cancer using the antibody and methods and kits utilized to diagnosing cancer. The herein described products and methods find utility in the context of a variety of cancers, such as pancreatic cancer, gastric cancer, liver cancer, prostate cancer, breast cancer, cervical cancer, bile duct cancer, lung cancer and esophageal cancer.
摘要翻译：本文描述了能够治疗或预防与DKK1的过表达和/或上调相关的癌症的抗体和抗体片段。还公开了使用抗体治疗或预防癌症的方法以及用于诊断癌症的方法和试剂盒。本文描述的产品和方法在各种癌症如胰腺癌，胃癌，肝癌，前列腺癌，乳腺癌，子宫颈癌，胆管癌，肺癌和食管癌的情况下发现有用。

2. 发明授权

US07943295B2 Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex 失效
标题翻译： NSCLC靶向CDCA1-KNTC2复合物的筛选和治疗方法
公开(公告)号：US07943295B2
公开(公告)日：2011-05-17
申请号：US11913142
申请日：2006-07-19
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C12Q1/00 , G01N33/574
CPC分类号： G01N33/57423 , G01N2500/02
摘要： The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.
摘要翻译：本发明是基于CDCA1和KNTC2的共激活及其同源相互作用在肺癌进展中起重要作用的观察，并且抑制复合物的方法可用于治疗非小细胞肺癌。

3. 发明申请

US20110027302A1 PEPTIDE VACCINES FOR LUNG CANCERS EXPRESSING TTK, URLC10 OR KOC1 POLYPEPTIDES 有权
标题翻译：用于表达TTK，URLC10或KOC1多肽的肺癌患者的抗生素疫苗
公开(公告)号：US20110027302A1
公开(公告)日：2011-02-03
申请号：US12903961
申请日：2010-10-13
申请人： Hideaki Tahara , Takuya Tsunoda , Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Hideaki Tahara , Takuya Tsunoda , Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K39/00 , A61P35/00
CPC分类号： C12N9/1211 , C12Q1/6886
摘要： The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.
摘要翻译：本发明提供了包含SEQ ID NO：8,67,89的氨基酸序列的肽以及包含上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失或添加，并具有细胞毒性T细胞诱导性。本发明还提供了用于治疗或预防包含这些肽的肿瘤的药物。本发明的肽也可以用作疫苗。

4. 发明授权

US07847060B2 Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides 有权
标题翻译：用于表达TTK，URLC10或KOC1多肽的肺癌的肽疫苗
公开(公告)号：US07847060B2
公开(公告)日：2010-12-07
申请号：US11816616
申请日：2006-02-17
申请人： Hideaki Tahara , Takuya Tsunoda , Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Hideaki Tahara , Takuya Tsunoda , Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K38/00 , A61K38/04 , A61K38/08
CPC分类号： C12N9/1211 , C12Q1/6886
摘要： The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.
摘要翻译：本发明提供了包含SEQ ID NO：8,67,89的氨基酸序列的肽以及包含上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失或添加，并具有细胞毒性T细胞诱导性。本发明还提供了用于治疗或预防包含这些肽的肿瘤的药物。本发明的肽也可以用作疫苗。

5. 发明申请

US20080254452A1 Pkp3 Oncogene as a Prognostic Indicator for Lung Cancer 失效
标题翻译： Pkp3致癌基因作为肺癌的预后指标
公开(公告)号：US20080254452A1
公开(公告)日：2008-10-16
申请号：US11577485
申请日：2005-10-18
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/57488 , C07K14/82 , G01N33/57423
摘要： The present invention provides the method of predicting an non-small cell lung cancer (NSCLC) prognosis.
摘要翻译：本发明提供了预测非小细胞肺癌（NSCLC）预后的方法。

6. 发明申请

US20110263012A1 SCREENING AND THERAPEUTIC METHOD FOR NSCLC TARGETING CDCA1-KNTC2 COMPLEX 审中-公开
标题翻译：用于NSCLC靶向CDCA1-KNTC2复合物的筛选和治疗方法
公开(公告)号：US20110263012A1
公开(公告)日：2011-10-27
申请号：US13080461
申请日：2011-04-05
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C12N15/63 , C07H21/02
CPC分类号： G01N33/57423 , G01N2500/02
摘要： The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.
摘要翻译：本发明是基于CDCA1和KNTC2的共激活及其同源相互作用在肺癌进展中起重要作用的观察，并且抑制复合物的方法可用于治疗非小细胞肺癌。

7. 发明授权

US07700573B2 Method for diagnosing non-small lung cancer 失效
标题翻译：诊断非小细胞肺癌的方法
公开(公告)号：US07700573B2
公开(公告)日：2010-04-20
申请号：US10593842
申请日：2005-03-18
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K31/70 , A01N43/64
CPC分类号： A61K31/731 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.
摘要翻译：公开了使用差异表达基因KIF11，GHSR1b，NTSR1和FOXM1检测非小细胞肺癌（NSCLC）的方法。还公开了基于KOC1和KIF11或NMU和GHSR1b或NTSR1之间的相互作用鉴定用于治疗和预防NSCLC的化合物的方法。

8. 发明申请

US20100009920A1 TTK AS TUMOR MARKER AND THERAPEUTIC TARGET FOR LUNG CANCER 审中-公开
标题翻译： TTK作为肿瘤标志物和肺癌的治疗目标
公开(公告)号：US20100009920A1
公开(公告)日：2010-01-14
申请号：US12518876
申请日：2007-12-12
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K38/10 , C07K16/00 , C07H21/04 , C07K14/00 , A61K31/7088 , A61P35/00 , C12Q1/68 , C07K7/08
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： Disclosed herein is a method for determining kinase activity of TTK for EGFR and methods of screening for modulators of this kinase activity. Also disclosed are methods and pharmaceutical compositions for preventing and/or treating lung cancer that use or include such modulators. Methods for diagnosing lung cancer using the kinase activity of TTK for EGFR protein as an index as well as methods for assessing and prognosing lung cancer are also provided.
摘要翻译：本文公开了用于确定EGFR的TTK的激酶活性的方法和筛选该激酶活性的调节剂的方法。还公开了用于预防和/或治疗使用或包括这种调节剂的肺癌的方法和药物组合物。还提供了使用TTK对EGFR蛋白的激酶活性作为指标诊断肺癌的方法以及肺癌的评估和预后的方法。

9. 发明申请

US20090317392A1 METHOD OF DIAGNOSING SMALL CELL LUNG CANCER 审中-公开
标题翻译：诊断小细胞肺癌的方法
公开(公告)号：US20090317392A1
公开(公告)日：2009-12-24
申请号：US11913273
申请日：2006-07-26
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K39/395 , A61K39/00 , C12Q1/68 , G01N33/53 , C12N15/63 , C40B30/04 , A61K31/7088 , C07H21/02
CPC分类号： C12N15/1135 , C12N2310/14 , C12Q1/6886 , C12Q2600/136
摘要： Objective methods for detecting and diagnosing small cell lung cancer (SCLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that discriminates between SCLC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that distinguishes two major histological types of lung cancer, non-small cell lung cancer (NSCLC) and SCLC. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of small cell lung cancer, methods of treating small cell lung cancer and method for vaccinating a subject against small cell lung cancer. Furthermore, the present invention provides chemotherapy resistant lung cancer- or SCLC-associated genes as diagnostic markers and/or molecular targets for therapeutic agent for these cancers. These genes are up-regulated in chemoresistant lung cancer or SCLC. Accordingly, chemoresistant lung cancer or SCLC can be predicted using expression level of the genes as diagnostic markers. As the result, any adverse effects caused by ineffective chemotherapy can be avoided, and more suitable and effective therapeutic strategy can be selected.
摘要翻译：本文描述了用于检测和诊断小细胞肺癌（SCLC）的客观方法。在一个实施方案中，所述诊断方法涉及确定区分SCLC细胞和正常细胞的SCLC相关基因的表达水平。在另一个实施方案中，诊断方法包括确定区分肺癌，非小细胞肺癌（NSCLC）和SCLC的两种主要组织学类型的SCLC相关基因的表达水平。最后，本发明提供了筛选用于治疗小细胞肺癌的治疗剂，治疗小细胞肺癌的方法和接种针对小细胞肺癌的受试者的方法。此外，本发明提供抗化学疗法的肺癌或SCLC相关基因作为用于这些癌症的治疗剂的诊断标记和/或分子靶标。这些基因在化疗耐药性肺癌或SCLC中上调。因此，可以使用基因的表达水平作为诊断标记来预测化学耐药性肺癌或SCLC。结果，可以避免无效化疗引起的任何不良反应，可以选择更合适有效的治疗策略。

10. 发明授权

US08771963B2 Method of diagnosing esophageal cancer 有权
标题翻译：诊断食管癌的方法
公开(公告)号：US08771963B2
公开(公告)日：2014-07-08
申请号：US13246639
申请日：2011-09-27
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C12Q1/00 , G01N1/00 , G01N33/53 , G01N33/566 , G01N33/567 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , Y10T436/25
摘要： In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer.
摘要翻译：为了鉴定涉及食管癌发生的分子以及可用于诊断标志物以及新药和免疫治疗靶标的分子，构建了代表32,256个基因的cDNA微阵列，分析19例食管鳞状细胞癌（ESCCS）的表达谱）通过激光捕获显微切割纯化。本文公开了在食管癌中显着上调或下调的基因组的详细全基因组数据库。这些基因可用于治疗药物或免疫治疗以及肿瘤标志物的开发。此外，本文公开了与淋巴结转移和手术后复发相关的基因。在候选分子靶基因中，进一步表征ECT2，CDC45L和DKK1。用ECT2或CDC45L的小干扰RNA（siRNA）处理ESCC细胞抑制癌细胞的生长。因此，本文的数据提供了用于鉴定诊断系统和用于食管癌的治疗靶分子的有价值的信息。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式